Learning outcomes

Students will be able:

  • to design an experimental study to identify therapeutic targets
  • to identify lead compounds
  • to characterize pharmacokinetic (PK) and pharmacodynamic (PD) properties of lead compounds
  • to assess in vitro and in vivo toxicity of lead compounds
  • to apply critical thinking and analytical skills to interpret data sets

Goals

This course provides a comprehensive overview of preclinical drug development process. Each stage of the process is developed in-depth and presented according to the current EMA (European Medicines Agency) legislation.

Content

  1. General Introduction: Drug Business- concepts & metrics
  2. Identification of Drug Targets
  3. Drug Discovery
  4. Preclinical Drug Development
  5. Pharmacokinetics
  6. Pharmacodynamics
  7. In vitro toxicology
  8. In vivo toxicology
  9. Reproductive and developmental toxicity

Table of contents

  • General Introduction

  • Drug Discovery

  • Preclinical Drug Development:

Pharmacodynamics

Pharmacokinetics

In vitro & in vivo toxicology

In vitro toxicology: Additional assays

  • Compliance with European and international guidelines with regard to animal welfare (3Rs)

  • Brief summary

Exercices

Not applicable

Teaching methods

Lectures.


Assessment method

Oral exam: /20

The exact modalities of the evaluation are likely to be modified during the preparation of the examination schedules, depending on the practical constraints with which the faculty administration may be confronted, or in the event of illness / force majeure / encroachment with an internship.

Sources, references and any support material

PowerPoint presentations, textbook of practicals, research and review articles.

Language of instruction

English
Training Study programme Block Credits Mandatory
Master in Biomedical Sciences Filière en gestion de la recherche clinique 1 3 Yes
Master in Biomedical Sciences Filière en recherche fondamentale et préclinique 1 3 Yes
Master in Biomedical Sciences Standard 1 3 Yes